01/05/2025 – AB Science today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time to complete their audit work Download PDF Post navigationPreviousPrevious post:European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaNextNext post:AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingRelated PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025Summary of the virtual conference held on October 16, 202516 October 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025
AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025
